Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Nucleobase is seeking seed funding of £250k to prototype the API and market it with partner institutions. Nucleobase will make efficient ethical genomic data sharing possible: Sharing and access to DNA sequencing data is limited due to privacy concerns and interoperability difficulties. The lack of sharing stops the progress of genomics research, affecting all disease research from cancers to rare diseases. The Team Fiona Nielsen @glyn_dk Founder & CEO of DNA Digest. #bioinformatics #genetics #computational #genomics Victor Szilagyi, @semiot Director of Nucleobase. #UI #UX #design #product #strategy #development Jelena Aleksic, @firegenome Advisor of Nucleobase. #genomics #bioinformatics #contract #strategy #writing Let’s have a Conversation. @dnadigest [email protected] [email protected] 07852239062 10a Capper Street, Wayra London, WC1E 6JA The DNAdigest platform is an API to securely query anonymised data: Nucleobase will develop and market the DNAdigest platform as a data broker solution providing on-demand access to aggregated statistics accessed securely across data locations. The result of each query is returned the user in a secure manner which keeps raw data fully anonymised through aggregation. Direct benefit for an exponentially growing market: Our target users are clinical geneticists and genetic researchers, both public and private. The DNA sequencing market is growing at an exponential rate (estimated 500k human genomes sequenced in 2015) and only a fraction of this data is currently made available for the research market in personalised medicine. Through direct user feedback, we have learnt our product has the potential to save 6months of the ~8 year $1.3bill drug discovery pipeline in pharma. Worldwide impact: DNAdigest will impact research in human health worldwide by shortening the time for drug development and accelerate genetic diagnosis from years to days. In addition, unlocking the silos of data will open up whole new markets for products based on big data DNAdigest Intellectual Property: The underlying mechanism for data aggregation and anonymisation is patented (Taysom & Cleevely) and has been applied before in the context of marketing data. DNAdigest has a perpetual licence to apply and sublicence this patented mechanism. Subscription model for access and incentives for growing users: Our business model is based on charging subscription fee tiered by the amount of queries available per month. The fees will be heavily discounted for institutions that connect their data for access through the platform API, and such providing a financial incentive for institutions to make their data available for secure queries. Profitable, sustainable and reaching market in 12months: The DNAdigest platform will launch our MVP for our first paying customers within 12 months of our first funding round. We are seeking 250k in investment please do get in touch to learn more about us and have a look at our investor deck.